MAPT and tauopathy: Immunization with PHF1, a monoclonal antibody that recognizes the phosphorylated residues Ser396/Ser404, resulted in an improvement in behavior on the traverse beam task and a reduction in tau pathology in the dentate gyrus of the hippocampus in tau transgenic mice [13, 21] as well as a significant delay in the onset of motor function decline and weight loss in the P301S tauopathy model [21].